These compounds have demonstrated significant efficacy in both cellular and in vivo studies, particularly in U87 glioma cells infected with the ZIKV FLR strain [255], with IC50 values ranging from 200–790 nM. Their mode of action involves binding to an allosteric pocket of NS3, which is a viable target within the Flavivirus protease. This binding occurs in contrast to the shallow active site, which typically recognizes polar and positively charged residues in the substrate, such as arginine (Arg) or lysine (Lys) [256]. Here, KRAS is linked to glioma.